PepTivator® SARS-CoV-2 Prot_S+

Stimulate T cells reactive to the spike protein of the SARS-CoV-2 Wuhan wild-type using PepTivator Peptide Pools. PepTivators are pools of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids overlap. PepTivator SARS-CoV-2 Prot_S+ is a pool of lyophilized peptides, covering the sequence domain aa 689–895 of the surface glycoprotein ("S") of SARS-Coronavirus 2 (GenBank MN908947.3, Protein QHD43416.1), also termed "spike" protein.

In contrast, PepTivator SARS-CoV-2 Prot_S Complete covers all functional domains (aa 5–1273), Prot_S covers selected immunodominan

... read more
Choose your product:

Related products for PepTivator® SARS-CoV-2 Prot_S+

Product data and images for PepTivator® SARS-CoV-2 Prot_S+
Figure 1

Schematic alignment of the spike glycoprotein and different SARS‑CoV‑2 PepTivator Peptide Pools based on this protein. PepTivator SARS‑CoV‑2 Prot_S covers the predicted immunodominant domains of the SARS‑CoV‑2 spike glycoprotein (protein S), PepTivator SARS‑CoV‑2 Prot_S1 covers the N-terminal S1 domain, PepTivator SARS‑CoV‑2 Prot_S+ covers a part of the C-terminal S2 domain, and PepTivator SARS-CoV-2 Prot_S Complete covers the whole protein sequence of the spike protein without the first 4 amino acids of the signal peptide.

Figure 2

Exemplary analysis of SARS-CoV-2–specific CD4+ and CD8+ T cells. A) PBMCs were stimulated with a mix of PepTivator SARS-CoV-2 Prot_N, Prot_M, and Prot_S or unstimulated as negative control. The data shows CD154 and TNF-α for CD4+ T cells and TNF-α and IFN-γ for CD8+ T cells. B/C). Either PepTivators covering the complete sequence of the nucleoprotein (N; PepTivator SARS-CoV-2 Prot_N), the membrane protein (M; PepTivator SARS-CoV-2 Prot_M), the spike protein (S; PepTivator SARS-CoV-2 Prot_S, Prot_S1, and Prot_S+), or the mix of all were used to stimulate SARS-CoV-2–reactive T cells. Frequencies of CD154+ within CD4+ T cells and TNF-α+ within CD8+ T cells are shown. In the quantitative analysis (B) each dot corresponds to one donor and in the heat maps (C) SARS-CoV-2–reactive T cell frequencies measured for each donor are color coded.

Figure 3

Quantitative analysis of spike protein–specific CD4+ T cells in convalescent COVID-19 donors. Quantitative analysis of SARS‑CoV‑2–specific CD4+ T cells of convalescent COVID-19 donors highlights that similar numbers of activated T cells can be observed whether the mix of three PepTivator Peptide Pools (PepTivator SARS-CoV-2 Prot_S, PepTivator SARS-CoV-2 Prot_S1, and PepTivator SARS-CoV-2 Prot_S+) or the single PepTivator SARS-CoV-2 Prot_S Complete is used.

Figure 4

Stimulation with SARS-CoV-2 PepTivator Peptide Pools reveals the presence of virus-specific CD4+ T cells after vaccination. A whole blood sample of a vaccinated donor was stimulated with the mix of three PepTivator Peptide Pools (PepTivator SARS-CoV-2 Prot_S, PepTivator SARS-CoV-2 Prot_S1, and PepTivator SARS-CoV-2 Prot_S+) or with PepTivator SARS-CoV-2 Prot_S Complete alone. Both, the applied mix of peptide pools as well as SARS-CoV-2 Prot_S Complete cover the complete sequence of the spike protein. As negative control, the sample was left unstimulated. T cell lineage surface markers and intracellular cytokines were stained, and cells were analyzed using a MACSQuant Analyzer 16. The presented plots are exemplary data showing CD154 and TNF-α for pregated CD4+ T cells.

Specifications for PepTivator® SARS-CoV-2 Prot_S+
Overview

Stimulate T cells reactive to the spike protein of the SARS-CoV-2 Wuhan wild-type using PepTivator Peptide Pools. PepTivators are pools of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids overlap. PepTivator SARS-CoV-2 Prot_S+ is a pool of lyophilized peptides, covering the sequence domain aa 689–895 of the surface glycoprotein ("S") of SARS-Coronavirus 2 (GenBank MN908947.3, Protein QHD43416.1), also termed "spike" protein.

In contrast, PepTivator SARS-CoV-2 Prot_S Complete covers all functional domains (aa 5–1273), Prot_S covers selected immunodominant sequence domains of the spike protein (aa 304–338, 421–475, 492–519, 683–707, 741–770, 785–802, and 885–1273) and Prot_S1 the complete N-terminal S1 domain (aa 1–692). The complete S2 domain (and parts of the S1 domain: aa 304–338, 421–475, and 492–519) is covered, when PepTivator SARS-CoV-2 Prot_S and Prot_S+ are combined.

In vitro stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.

Detailed product information
Background information

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), also known as novel coronavirus 2019-nCoV, causes fever, severe respiratory illness, and can lead to life threatening pneumonia. The first cases of this disease, termed COVID-19 for coronavirus disease 2019, have been detected in December 2019 in Wuhan, China. SARS-CoV-2 Prot_S stands for the surface glycoprotein of SARSCoV-2, the “spike protein”. This protein is responsible for the recognition and binding of the coronavirus to the host cell. Once SARS-CoV-2 has bound to the ACE2 receptor of the host cell, fusion of viral envelope and host cell membrane starts, which enables the viral genome to enter the host cell1,2. Thus, the spike proteins are crucial for the infection of cells with coronaviruses and have been suggested as possible target for vaccine development.

The PepTivator® SARS-CoV-2 Prot_S+ covers the gaps in the sequence mapping between aa 689 and 895 of the PepTivator SARS-CoV-2 Prot_S. Both PepTivators can be combined to cover the complete C-terminal S2 domain of the spike protein, which is cleaved from the S1-domain by a furin protease3,4. In contrast, PepTivator SARS-CoV-2 Prot_S Complete covers all functional domains (aa 5–1273) and Prot_S1 the complete N-terminal S1 domain (aa 1–692).

Applications

PepTivator® SARS-CoV-2 Prot_S+ – research grade has been specifically developed for in vitro stimulation of SARS-CoV-2–specific T cells. Peptides of 15 amino acids in length and 11 amino acids overlap represent an optimized solution for stimulating both CD4+ and CD8+ T cells in various applications, including:

  • The PepTivator SARS-CoV-2 Prot_S+ can be combined with PepTivator SARS-CoV-2 Prot_S (# 130-126-700; # 130-126-701) for covering the complete C-terminal S2-domain of the spike protein (and parts of the S1 domain: aa 304–338, 421–475, and 492–519).
  • Detection and analysis of SARS-CoV-2–specific CD4+ and CD8+ effector/memory T cells in PBMCs by MACS® Cytokine Secretion Assays, intracellular cytokine staining, or other technologies.
  • Isolation of viable SARS-CoV-2–specific CD4+ T cells with the CD154 MicroBead Kit, or of viable CD4+ and CD8+ T cells using MACS Cytokine Secretion Assay – Cell Enrichment and Detection Kits. Subsequently, cells can be expanded for generation of T cell lines.
  • Generation of SARS-CoV-2–specific CD4+ and CD8+ effector / memory T cells from naive T cell populations.
  • Pulsing of antigen-presenting cells, e.g. for research on dendritic cell vaccination.
Citations for PepTivator® SARS-CoV-2 Prot_S+
Publications
  1. Strafella, C. et al. (2021) Case Report: Sars-CoV-2 Infection in a Vaccinated Individual: Evaluation of the Immunological Profile and Virus Transmission Risk. Front Immunol 12 (doi: 10.3389/fimmu.2021.708820)
  2. Aiello, A. et al. (2021) Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients. Int J Infect Dis 106: 338-347
  3. Mazzoni, A. et al. (2021) First dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in ex COVID-19 subjects. J. Clin. Invest. 131 (12): doi: 10.1101/2021.03.05.21252590

You have previously chosen International as your location.
What do you want to do?